Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma

Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have improved the prognosis of advanced-stage non-small cell lung cancer (NSCLC) with ALK rearrangement, but resistance mechanisms limit their efficacy. We describe the case of a 63-year-old man with a stage cIVA ALK-rearranged lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Pasau, Thomas, Wauters, Els, Wauters, Isabelle, Duplaquet, Fabrice, Pirard, Lionel, Pop-Stanciu, Claudia, D’Haene, Nicky, Dupont, Michael, Vander Borght, Thierry, Rondelet, Benoît, Ocak, Sebahat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677532/
https://www.ncbi.nlm.nih.gov/pubmed/36419902
http://dx.doi.org/10.3389/fonc.2022.985446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677532/
https://www.ncbi.nlm.nih.gov/pubmed/36419902
http://dx.doi.org/10.3389/fonc.2022.985446

Ejemplares similares